Latest Commercialisation News

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Dotz Nano has pushed out the maturity dates on its convertible notes to March 2027, securing continued backing from Mercer Street Capital. The move introduces new conversion limits and an option for cash settlements, signalling confidence in Dotz’s carbon capture ambitions.

Norwood Systems has expanded its CogVoice project with an additional A$595,000 contract variation, reinforcing its role in a major Australian telco’s platform modernisation.

Zeotech Limited's methane control technology has delivered a 92% reduction in methane emissions during initial field trials at a Queensland landfill, signalling promising real-world performance for its zeoteCH4® biofilter solution.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

Spenda Limited (ASX: SPX) has voluntarily suspended trading of its shares from 2 June 2026 to manage disclosure around its institutional accelerated renounceable entitlement offer (AREO). The suspension is expected to last until 10 June or until the AREO results are announced.

Challenger Gold has poured its first gold bar from the Hualilán project in Argentina, initiating a production ramp-up under a toll milling agreement that secures processing capacity for three years.

Imagion Biosystems has secured FDA clearance to proceed with its Phase 1b/2 trial of the MagSense® HER2 Imaging Agent, targeting improved detection of HER2+ breast cancer. Patient recruitment is expected to start in Q3 2026, marking a crucial step toward commercialisation.

Morella Corporation’s latest drilling at Mt Edon delivers broad and continuous rubidium mineralisation with high-grade pockets, setting the stage for its first JORC Mineral Resource Estimate.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

FortifAI has appointed Kelly Herrell, a seasoned Silicon Valley CEO with a track record of scaling infrastructure tech companies to IPO and acquisition, as its new CEO. Herrell’s leadership aims to accelerate commercialisation of FortifAI’s AI Data Plane technology through its Nol8 subsidiary.